<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191525</url>
  </required_header>
  <id_info>
    <org_study_id>PROBIDEM</org_study_id>
    <nct_id>NCT04191525</nct_id>
  </id_info>
  <brief_title>Phase II Clinical Trial to Evaluate the Efficacy and Safety of the Treatment With BPL-1 in Adult Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A 12 Week, Randomized, Double-blind, Placebo-controlled, Phase II Trial to Evaluate the Efficacy and Safety of the Treatment With BPL-1 in Adult Patients With Type 2 Diabetes Mellitus With Different Course of Disease and Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mónica Marazuela Azpíroz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alba Garcimartín Álvarez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carolina Knott Torcal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nerea Aguirre Moreno</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Miguel Antonio Sampedro Núñez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>María Caldas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Belén Ruiz-Rosso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ana María Ramos Levi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes Mellitus type 2 (T2DM) is a chronic and progressive disease, characterized mainly by&#xD;
      hyperglycemia. Metabolic imbalance causes an increased risk of microvascular and&#xD;
      macrovascular complications associated with the increased prevalence of cardiovascular&#xD;
      disease (CVD) in diabetics.&#xD;
&#xD;
      Although genetic predisposition determines individual susceptibility to T2DM, external&#xD;
      factors such as an unhealthy diet and a sedentary lifestyle condition the onset of the&#xD;
      disease.&#xD;
&#xD;
      Since T2DM is a multifactorial disease, many authors have studied the possible role of the&#xD;
      microbiota and its alterations in the pathophysiology of the disease. There is evidence that&#xD;
      in T2DM there are alterations in the proportion of Firmicutes, Bacteroidetes and&#xD;
      Proteobacteria, and a smaller amount of bifidobacteria with anti-inflammatory properties.&#xD;
&#xD;
      Probiotics are living microorganisms present in food that, if consumed in sufficient&#xD;
      quantities, can improve health. In general, probiotics protect the patient through&#xD;
      immunomodulation, protecting him from infections, increasing the activation of mononuclear&#xD;
      cells and lymphocytes.&#xD;
&#xD;
      The investigational product is a supplement to the probiotic Bifidobacterium animalis subsp.&#xD;
      lactis (BPL-1) CECT 8145. There are numerous studies carried out on different strains of&#xD;
      GLP-1 that demonstrate its safety. Many of them are commonly used in the food industry, not&#xD;
      only because of their proven safety, but also because of their viability until consumption.&#xD;
&#xD;
      This clinical trial is proposed as an interdisciplinary study that can contribute to the&#xD;
      characterization of the efficacy of treatment with probiotics in patients with T2DM of&#xD;
      different stages of evolution, without and with hepatic involvement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Actual">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">June 26, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-centre, randomized, double-blind clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fasting glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycated haemoglobin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Glycated haemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Insulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>12 weeks</time_frame>
    <description>HOMA-IR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>HDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>LDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>12 weeks</time_frame>
    <description>Triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Body Mass Index (BMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Fat Percentage (%BF)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Body Fat Percentage (%BF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist perimeter</measure>
    <time_frame>12 weeks</time_frame>
    <description>Waist perimeter</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mediterranean diet adherence score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mediterranean diet adherence score</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BPL-1 Probiotic capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BPL-1 Probiotic 1 capsule/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>BPL-1 Probiotic capsules</intervention_name>
    <description>BPL-1 Probiotic 1 capsule/day</description>
    <arm_group_label>BPL-1 Probiotic capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo masked with the same presentation as the experimental product 1 capsule/day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients between the ages of 18-75 (inclusive)&#xD;
&#xD;
          -  BMI ≥ 27&#xD;
&#xD;
          -  Glycated hemoglobin &gt; 5,6 and/or fasting glucose &gt; 100 mg/dl and/or being on active&#xD;
             treatment with at least one antidiabetic medication&#xD;
&#xD;
          -  Subjects must be able to provide written informed consent&#xD;
&#xD;
          -  Females of childbearing potential must have a previous negative pregnancy test and&#xD;
             must agree to use adequate contraception during their participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Crohn's disease, liver cirrhosis, human immunodeficiency virus (HIV) or any other&#xD;
             active systemic bacterial, viral or fungal infections&#xD;
&#xD;
          -  BMI &gt; 42&#xD;
&#xD;
          -  Severe hypoglycemias within 3 months prior to the start date of the study&#xD;
&#xD;
          -  Abnormal glycated hemoglobin measurements (over 8%) prior to the start date of the&#xD;
             study&#xD;
&#xD;
          -  Prescription of a new antidiabetic medication in the last 6 months&#xD;
&#xD;
          -  Celiac disease or any other food intolerances&#xD;
&#xD;
          -  Use of antibiotics, probiotics and/or prebiotics within 2 weeks prior to the start&#xD;
             date of the study&#xD;
&#xD;
          -  Chronic liver disease with a C Child-Plug score, chronic kidney disease with&#xD;
             creatinine clearance &lt; 50 ml/min as well as any other clinically significant&#xD;
             conditions including pulmonary, neurological and cardiovascular diseases according to&#xD;
             the investigators medical opinion&#xD;
&#xD;
          -  Patients with history or presence of malignancy who have been treated with systemic&#xD;
             antineoplastic therapy within 6 months prior to the start date of the study&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Not being able to provide written informed consent to participate in the study or to&#xD;
             cooperate and comply with the study procedures for any other reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mónica Marazuela Azpíroz, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de La princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</investigator_affiliation>
    <investigator_full_name>Mónica Marazuela Azpíroz</investigator_full_name>
    <investigator_title>Head of Endocrinology and Nutrition</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Microbiote</keyword>
  <keyword>Cardiovascular Risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

